New Drug Application Nda And Supplemental Nda Snda Requirements Cases in D.C. Circuit

Browse 1 new drug application nda and supplemental nda snda requirements cases decided by D.C. Circuit. AI-powered summaries, holdings, and legal analysis.

1
Cases
1
Mixed

New Drug Application Nda And Supplemental Nda Snda Requirements Opinions from D.C. Circuit (1)

Vanda Pharmaceuticals, Inc. v. FDA

D.C. Circuit Reverses FDA's Rejection of Vanda's Hetlioz sNDA for Pediatric Use

D.C. Circuit · 2025-08-15 · Mixed · Impact: 65/100

Vanda Pharmaceuticals, Inc. v. FDA, decided by D.C. Circuit on August 15, 2025, resulted in a mixed outcome. The D.C. Circuit reviewed the FDA's refusal to approve Vanda Pharmaceuticals' supplemental ...

Frequently Asked Questions

Q: How many new drug application nda and supplemental nda snda requirements cases has D.C. Circuit decided?

CaseLawBrief currently tracks 1 new drug application nda and supplemental nda snda requirements cases from D.C. Circuit. This number is updated as new opinions are published.

Q: What types of outcomes occur in new drug application nda and supplemental nda snda requirements cases at D.C. Circuit?

Outcome breakdown: Mixed: 1.

Q: Where can I find plain English summaries of new drug application nda and supplemental nda snda requirements rulings from D.C. Circuit?

Each case page on CaseLawBrief includes an AI-generated plain English summary, key holdings, and legal analysis. Click any case above to read its full analysis.

Explore More

All D.C. Circuit Cases All New Drug Application Nda And Supplemental Nda Snda Requirements Cases All Courts All Topics Search